Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 111–120, page 12 of 20. Filter these by subject, year and score in the research library →

1. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trialsResearch summary

   Research summaries · alzhub.org/study/the-efficacy-and-safety-of-lecanemab-10-mg-kg-biweekly-compared-to-a-38565747

   … effective interventions. Lecanemab, a monoclonal antibody targeting amyloid-beta plaques, shows promise in slowing Alzheimer's progression. Positive clinical trial results have instilled hope in patients, prompting ongoing …

2. Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future researchResearch summary

   Research summaries · alzhub.org/study/use-of-lecanemab-and-donanemab-in-the-canadian-healthcare-system-39893139

   Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform …

3. Are Deep White Matter Hyperintensities Associated with Amyloid-Related Imaging Abnormalities in Patients with Alzheimer Disease Treated with Lecanemab?Research summary

   Research summaries · alzhub.org/study/are-deep-white-matter-hyperintensities-associated-with-amyloid-41038644

   … with AD treated with lecanemab. These findings suggest that DWMH may serve as a potential imaging biomarker for ARIA risk stratification. Larger studies incorporating additional vascular biomarkers, including cerebral amyloid …

4. Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Focused on LecanemabResearch summary

   Research summaries · alzhub.org/study/practical-guide-of-the-korean-association-for-geriatric-psychiatry-to-40696527

   … disease modification. Lecanemab, a humanized mAb targeting soluble Aβ protofibrils and plaque, received regulatory approval in Korea in July 2024, following global randomized controlled trial data demonstrating its efficacy to …

5. Real world clinical practice of lecanemab at PUMCH dementia cohort: focus on dynamic imaging and biomarker evolutionResearch summary

   Research summaries · alzhub.org/study/real-world-clinical-practice-of-lecanemab-at-pumch-dementia-cohort-41520099

   … this real-world cohort, lecanemab reduced amyloid on PET scans, and although cognitive and functional scores still worsened, the rate of progression was slower than in a control group. Brain imaging also showed volume reduction …

6. Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health SystemResearch summary

   Research summaries · alzhub.org/study/real-world-characterization-of-amyloid-related-imaging-abnormalities-4202aa20

   … of patients receiving lecanemab. Methods In this retrospective cohort study from the Mass General Brigham Alzheimer’s Therapeutic Program, we analyzed data from 468 patients with early Alzheimer’s disease who were at least 90 …

7. Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/fatal-iatrogenic-cerebral-amyloid-related-arteritis-in-a-woman-38086820

   … the experimental drug lecanemab. She was randomized to the placebo group and subsequently enrolled in an open-label extension which guaranteed she received the active drug. After the third biweekly infusion, she suffered a …

8. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and LecanemabResearch summary

   Research summaries · alzhub.org/study/impact-of-anti-amyloid-monoclonal-antibodies-on-the-pathology-and-35493943

   … gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. …

9. Lecanemab (Leqembi)Research summary

   Research summaries · alzhub.org/study/lecanemab-leqembi-25dfc5ad

   Canada’s Drug Agency (CDA-AMC) recommends that Leqembi be reimbursed by public drug plans for the treatment of adult patients in the early stages of Alzheimer disease (AD) (i.e., mild cognitive impairment [MCI] or mild dementia) …

10. Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world studyResearch summary

    Research summaries · alzhub.org/study/amyloid-related-imaging-abnormalities-in-japanese-patients-with-41936348

    … Japanese AD cohort, Lecanemab demonstrated a manageable safety profile in a real-world setting. In exploratory analyses, potential trends toward a higher frequency of ARIA were observed in patients with lower MMSE scores, higher …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.